3Q26: Revenue Growth Accelerated Markedly
发布时间:2026-10-22 来源:华泰证券
For 9M26, revenue increased by 36.43% YoY to RMB1,770mn, driven by business expansion, distribution network optimization, and enhanced advertising events; the attributable net profit was RMB362mn (+11.35% YoY), and the recurring attributable net profit was RMB256mn (+0.95% YoY). For 3Q26, revenue was RMB614mn (+41.37% YoY), the attributable net profit was RMB106mn (+11.08% YoY), and the recurring attributable net profit was RMB89mn (+2.02% YoY), which included RMB21mn of investment income from large-value certificates of deposit and other wealth-management products. Revenue growth accelerated notably in 3Q26 vs 2Q26, but the attributable NPM saw a phased YoY decline amid product-mix changes and stepped-up promotions. Looking to 4Q26, should core products such as the white mask sustain their steady performance and PDRN and oil-based products continue ramping up, with earlier promotional spending starting to pay off and the Double 11 shopping festival kicking in, revenue is poised to sustain rapid growth. Maintain OVERWEIGHT.
Ample products in the pipeline
According to Voolga’s official account, in July the brand launched products including a glow-boosting moisturizing body tone-up cream and an ice cream cleansing balm; in September it launched the Queen Capsule Oil, Revitalizing Oil and Gilded Oil, strengthening its deployment in the oil-based skincare segment; and in October it launched medical device-registered products such as a sterile derma roller and a medical sodium hyaluronate ectoine repair dressing. The company also published the Voolga PDRN White Paper on Science-Based Skincare and Transdermal Technology Innovation, setting a new standard for topical PDRN. According to the NMPA, in September the company completed filings for products including a ginseng anti-wrinkle plumping eye cream/serum and a DNA sodium radiance-boosting firming essence/lotion/compress mask, enriching its anti-wrinkle and repair product reserves.
GPM declined, sales expense ratio rose
1) For 3Q26, the GPM was 76.83% (-3.57pp YoY); for 9M26, the GPM was 76.86% (-4.25pp YoY), with the year-to-date decline driven by changes in the sales product mix. 2) Expense ratios: For 3Q26, the sales/administrative/R&D expense ratios were 50.55/4.04/1.87% (+4.24/-1.35/-1.12pp YoY); the financial expense ratio was -0.14% (+1.83pp YoY). Year to date, the company has increased promotional investment and shifted idle proprietary funds into entrusted wealth management, which reduced deposit interest income, affecting the cumulative sales expense ratio and financial expense ratio, respectively. 3) Inventory: Inventory stood at RMB330mn at end-3Q26, up by 99.04% in 9M26, mainly due to stockpiling for major shopping events.
Earnings forecasts and valuation
Considering the company’s rapid revenue growth in 3Q26, driven by business expansion, distribution network optimization, and enhanced advertising events, we raise our 2026/2027/2028 revenue forecasts by 6.8/6.8/6.5% to RMB2,510/2,885/ 3,243mn. To reflect the GPM softness owing to product-mix changes and a higher sales-expense ratio stemming from enhanced advertising events, we lower our attributable net profit forecasts by 4.2/3.8/4.2% to RMB470/531/591mn, with EPS of RMB0.90/1.02/1.14. To reflect the company’s leadership as a professional skincare brand, we largely maintain our premium ratio and value the stock at 25x 2027E PE, above its peers’ average of 19x on iFinD consensus. We trim our target price to RMB25.53 (previous: RMB29.25, based on 31x 2026E PE).
Risks: sharp increases in the sales-expense ratio, intensifying competition, and new product sales falling short of our expectations.